利伐沙班与华法林治疗非瓣膜性心房颤动的临床综合评价
Clinical Comprehensive Evaluation of Rivaroxaban and Warfarin in the Treatment of Nonvalvular Atrial Fibrillation
王超花 1于焕君 1郭瑞臣2
作者信息
- 1. 山东省东阿县人民医院药学部,山东 聊城 252200
- 2. 山东大学齐鲁医院临床药理研究所,济南 250000
- 折叠
摘要
目的:构建利伐沙班综合评价指标体系,用于利伐沙班与华法林治疗非瓣膜性心房颤动的临床综合评价,为卫生政策制定和临床合理用药提供循证证据.方法:采用德尔菲法和层次分析法建立综合评价指标体系并确定各指标权重,通过临床观察研究、Meta分析、调查问卷、药品说明书、指南共识和官方网站等搜集相关证据资料,由专家根据安全性、有效性、经济性、适宜性、可及性和创新性各维度证据资料对利伐沙班和华法林治疗非瓣膜性心房颤动分别进行评分,结合指标权重和专家评分得到指标最终得分,各指标得分累加得利伐沙班和华法林综合评价总分,比较两者总分.结果:所构建的利伐沙班综合评价体系包括 6 个一级指标和 21 个二级指标;利伐沙班综合评价得分为 85.12 分,华法林综合评价得分为 71.45 分.结论:利伐沙班用于非瓣膜性心房颤动的临床综合价值高于华法林,可为国家医保政策和临床合理用药提供参考依据.
Abstract
OBJECTIVE:To construct the comprehensive evaluation index system of rivaroxaban for clinical comprehensive evaluation of rivaroxaban and warfarin in the treatment of nonvalvular atrial fibrillation,so as to provide evidence-based evidence for health policy formulation and clinical rational drug use.METHODS:The Delphi and Analytic Hierarchy Process were used to establish a comprehensive evaluation index system and determine the weights of each indicator.Relevant evidence data were collected through clinical observation studies,Meta-analysis,questionnaires,drug instructions,guideline consensus and official website,the experts scored rivaroxaban and warfarin in the treatment of nonvalvular atrial fibrillation according to the evidence data of safety,effectiveness,economy,suitability,accessibility and innovation.Final score of the indicator was obtained by combining the weight of the indicator and the expert score.The total score of rivaroxaban and warfarin were added together,and the total score of the two was compared.RESULTS:The constructed comprehensive evaluation system of rivaroxaban included 6 first-level indicators and 21 second-level indicators;the comprehensive evaluation score of rivaroxaban was 85.12 points,and the comprehensive evaluation score of warfarin was 71.45 points.CONCLUSIONS:The clinical comprehensive value of rivaroxaban is higher than that of warfarin in the treatment of nonvalvular atrial fibrillation,which can provide reference basis for national medical insurance policies and rational clinical medication.
关键词
利伐沙班/华法林/心房颤动/临床综合评价Key words
Rivaroxaban/Warfarin/Atrial fibrillation/Clinical comprehensive evaluation引用本文复制引用
基金项目
山东省卫生健康委员会-山东省第二批药品临床综合评价项目(2022YZ018)
出版年
2024
国家科技期刊平台
NSTL
万方数据